Tenax Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.42
- 52-Week Range
- $1.31 – $19.40
- Market Cap
- $65.12M
- P/E (TTM)
- —
- EPS (TTM)
- -1.39
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.71
- PEG Ratio
- 1.44
- Return on Equity
- -64.20%
- Return on Assets
- -39.54%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 14.01
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-27.05M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-37.07M
Market Snapshot
About
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market. The company is developing levosimendan, a calcium sensitizer, for the treatment of pulmonary hypertension associated with heart failure. Tenax aims to address unmet medical needs in cardiovascular and pulmonary diseases.